Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi.

NCT00412893 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00412893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00412893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi.
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
March 7, 2007
Completion date
March 28, 2013
Enrollment
527 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

aspergillosis, invasive fungal infection